Current treatment of gram-positive infections: focus on efficacy, safety, and cost minimalization analysis of teicoplanin

Hosp Formul. 1992 Dec;27(12):1199-200, 1203-4, 1207-10.


The current health care environment has had a significant impact on hospital Pharmacy and Therapeutics Committee formulary decisions. In evaluating a new therapy for formulary inclusion, a cost savings along with equivalent or an improvement in patient care and safety is optimal. Teicoplanin is an investigational glycopeptide antimicrobial agent with a spectrum of activity similar to vancomycin. Unlike vancomycin, however, teicoplanin has a long elimination half-life permitting administration once daily, and is well tolerated when given intramuscularly. In addition, teicoplanin is associated with a favorable safety profile. Red man syndrome does not appear to be a significant clinical problem. Results of our cost minimalization analysis using the average acquisition costs of vancomycin revealed that teicoplanin (400 mg), at an average acquisition cost of less than $28.46 when administered intravenously and $30.93 when administered intramuscularly, offers a clinically efficacious, safe, and less expensive alternative to vancomycin therapy.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cost Savings
  • Drug Costs / statistics & numerical data*
  • Drug Evaluation
  • Formularies, Hospital as Topic*
  • Gram-Positive Bacterial Infections / drug therapy*
  • Humans
  • Safety
  • Teicoplanin / administration & dosage*
  • Teicoplanin / economics
  • Treatment Outcome
  • United States
  • Vancomycin / administration & dosage
  • Vancomycin / economics


  • Teicoplanin
  • Vancomycin